FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280493740> ?p ?o ?g. }

• W4280493740 endingPage "402" @default.
• W4280493740 startingPage "384" @default.
• W4280493740 abstract "Background: The overexpression of human epidermal growth factor receptor 2 (HER2) is commonly associated with metastatic breast cancer and epithelial ovarian cancer. The U.S. Food and Drug Administration (FDA) has approved Trastuzumab as an anti-HER2 agent for the metastatic breast and epithelial ovarian cancer. However, Trastuzumab has severe limitations in the treatment of metastatic breast cancer associated with ligand-dependent dimerization of HER2 receptor at the extracellular domain-II (ECD-II) region. The therapeutic approach in combination of pertuzumab and trastuzumab is found to be effective in preventing HER2 dimerization at the ECD-II region. The radioimmunotherapeutic approach, utilizing both these anti-HER2 agents (trastuzumab/pertuzumab), radiolabeled with [177Lu]Lu3+, has proved to be clinically efficacious with promising potential. Toward this, the formulation for clinical doses of [177Lu]Lu-DOTA-pertuzumab has been optimized using medium specific activity (0.81 GBq/μg) [177Lu]LuCl3. Materials and Methods: Preconcentrated pertuzumab was conjugated with p-NCS-benzyl-DOTA. Purified DOTA-benzyl-pertuzumab conjugate was radiolabeled with carrier-added [177Lu]LuCl3. Quality control parameters were evaluated for the [177Lu]Lu-DOTA-pertuzumab. In vivo biodistribution was carried out at different time points postadministration. Specific cell binding, immunoreactivity, and internalization were investigated by using SKOV3 and SKBR3 cells. Results: In this study, the authors reported a consistent and reproducible protocol for clinical dose formulations of [177Lu]Lu-DOTA-pertuzumab, with a radiochemical yield of 86.67% ± 1.03% and radiochemical purity (RCP) of 99.36% ± 0.36% (n = 10). Preclinical cell binding studies of [177Lu]Lu-DOTA-pertuzumab revealed specific binding with SKOV3 and SKBR3 cells up to 24.4% ± 1.4% and 23.2% ± 0.8%, respectively. The uptakes in SKOV3- and SKBR3-xenografted tumor in severe combined immunodeficiency mice were observed to be 25.9% ± 0.8% and 25.2% ± 1.2% ID/g at 48 and 120 h postinjection, respectively. Conclusions: A protocol was optimized for the preparation of ready-to-use clinical dose of [177Lu]Lu-DOTA-pertuzumab, in hospital radiopharmacy settings. The retention of RCP of the radiopharmaceutical, on storage in saline and serum, at -20°C, up to 120 h postradiolabeling, confirmed its in vitro stability." @default.
• W4280493740 created "2022-05-22" @default.
• W4280493740 creator A5021696019 @default.
• W4280493740 creator A5022053889 @default.
• W4280493740 creator A5028672629 @default.
• W4280493740 creator A5047673710 @default.
• W4280493740 creator A5053621783 @default.
• W4280493740 creator A5068217246 @default.
• W4280493740 creator A5076843769 @default.
• W4280493740 creator A5079805899 @default.
• W4280493740 creator A5080605033 @default.
• W4280493740 creator A5083071295 @default.
• W4280493740 date "2022-06-01" @default.
• W4280493740 modified "2023-10-01" @default.
• W4280493740 title "Clinical Dose Preparation of [¹⁷⁷Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷Lu]LuCl₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression" @default.
• W4280493740 cites W1533229981 @default.
• W4280493740 cites W1550092936 @default.
• W4280493740 cites W1897236478 @default.
• W4280493740 cites W1930581861 @default.
• W4280493740 cites W1971666451 @default.
• W4280493740 cites W1975730315 @default.
• W4280493740 cites W2007107550 @default.
• W4280493740 cites W2012223968 @default.
• W4280493740 cites W2017693082 @default.
• W4280493740 cites W2027719026 @default.
• W4280493740 cites W2034003932 @default.
• W4280493740 cites W2052292334 @default.
• W4280493740 cites W2058426435 @default.
• W4280493740 cites W2061335345 @default.
• W4280493740 cites W2063085381 @default.
• W4280493740 cites W2064394610 @default.
• W4280493740 cites W2074270635 @default.
• W4280493740 cites W2082255225 @default.
• W4280493740 cites W2085055581 @default.
• W4280493740 cites W2089630677 @default.
• W4280493740 cites W2089929576 @default.
• W4280493740 cites W2092187686 @default.
• W4280493740 cites W2095156669 @default.
• W4280493740 cites W2098666653 @default.
• W4280493740 cites W2119940209 @default.
• W4280493740 cites W2126831997 @default.
• W4280493740 cites W2151425644 @default.
• W4280493740 cites W2153942473 @default.
• W4280493740 cites W2220869574 @default.
• W4280493740 cites W2322662384 @default.
• W4280493740 cites W2342454653 @default.
• W4280493740 cites W2343442843 @default.
• W4280493740 cites W2615655254 @default.
• W4280493740 cites W2736624409 @default.
• W4280493740 cites W2789357466 @default.
• W4280493740 cites W2872877360 @default.
• W4280493740 cites W2901327888 @default.
• W4280493740 cites W2970803602 @default.
• W4280493740 cites W2972399366 @default.
• W4280493740 cites W2982496779 @default.
• W4280493740 cites W2996948756 @default.
• W4280493740 cites W2997155063 @default.
• W4280493740 cites W3011983932 @default.
• W4280493740 cites W3047380786 @default.
• W4280493740 cites W3099080752 @default.
• W4280493740 cites W3099316220 @default.
• W4280493740 cites W3139333239 @default.
• W4280493740 cites W4211120843 @default.
• W4280493740 cites W4293247451 @default.
• W4280493740 cites W4302031722 @default.
• W4280493740 doi "https://doi.org/10.1089/cbr.2021.0230" @default.
• W4280493740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35575711" @default.
• W4280493740 hasPublicationYear "2022" @default.
• W4280493740 type Work @default.
• W4280493740 citedByCount "1" @default.
• W4280493740 countsByYear W42804937402023 @default.
• W4280493740 crossrefType "journal-article" @default.
• W4280493740 hasAuthorship W4280493740A5021696019 @default.
• W4280493740 hasAuthorship W4280493740A5022053889 @default.
• W4280493740 hasAuthorship W4280493740A5028672629 @default.
• W4280493740 hasAuthorship W4280493740A5047673710 @default.
• W4280493740 hasAuthorship W4280493740A5053621783 @default.
• W4280493740 hasAuthorship W4280493740A5068217246 @default.
• W4280493740 hasAuthorship W4280493740A5076843769 @default.
• W4280493740 hasAuthorship W4280493740A5079805899 @default.
• W4280493740 hasAuthorship W4280493740A5080605033 @default.
• W4280493740 hasAuthorship W4280493740A5083071295 @default.
• W4280493740 hasConcept C121608353 @default.
• W4280493740 hasConcept C126322002 @default.
• W4280493740 hasConcept C150903083 @default.
• W4280493740 hasConcept C159654299 @default.
• W4280493740 hasConcept C185592680 @default.
• W4280493740 hasConcept C191560914 @default.
• W4280493740 hasConcept C202751555 @default.
• W4280493740 hasConcept C203014093 @default.
• W4280493740 hasConcept C207001950 @default.
• W4280493740 hasConcept C2775930923 @default.
• W4280493740 hasConcept C2776146153 @default.
• W4280493740 hasConcept C2776872082 @default.
• W4280493740 hasConcept C2777325958 @default.
• W4280493740 hasConcept C2777807558 @default.
• W4280493740 hasConcept C2779786085 @default.
• W4280493740 hasConcept C2779931791 @default.

• next